NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中國的Pertuzumab市場的相關調查報告書(2021年∼2025年)

Investigation Report on China's Pertuzumab Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1009412
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Pertuzumab市場的相關調查報告書(2021年∼2025年) Investigation Report on China's Pertuzumab Market 2021-2025
出版日期: 2021年06月04日內容資訊: 英文 50 Pages
簡介

Pertuzumab進入中國市場以來,銷售額急速成長,從2019年的2,115萬人民幣,2020年達成5億169萬人民幣,銷售額的年度成長率成為2272.15%。從Pertuzumab的價格降低為基礎,2021年到2025年,其銷售量預計持續成長。

Pertuzumab,2020年首次列入醫療保險的償付目錄,0.42g的1回劑量的價格從1萬8,800元降低到4,955元。這個價格到2021年終有效。還有Pertuzumab的價格未來預計再次降低。此次的降價使患者的負擔減輕,Pertuzumab的使用率高漲,預期銷售增加。

本報告提供中國的Pertuzumab市場的相關調查,市場規模和預測,價格,成長要素和機會等市場發展的影響因素分析,競爭情形,主要製造商/產品的簡介等資訊。

目錄

第1章 Pertuzumab的相關概念

  • Pertuzumab的適應症
  • 中國的Pertuzumab的開發
  • 中國的Pertuzumab的政府核准
  • COVID-19對中國的Pertuzumab銷售的影響

第2章 中國的Pertuzumab銷售(2019-2020)

  • Pertuzumab的銷售額
    • 總銷售額
    • 各地區的銷售額
  • Pertuzumab的銷售量
    • 整體銷售量
    • 各地區銷售量
  • 中國的各劑型Pertuzumab銷售(2019-2020)
    • 注射
    • 其他的劑型分析

第3章 中國的主要Pertuzumab製造商分析(2019-2020)

  • 主要Pertuzumab製造商市場佔有率分析
    • 各銷售額市場佔有率調查
    • 各銷售額市場佔有率調查
  • Roche Pharma(Schweiz)AG
    • 企業簡介
    • PERJETA(Roche Pharma(Schweiz)AG的Pertuzumab)的中國的銷售

第4章 中國的各製造商Pertuzumab的價格(2020-2021)

  • Roche Pharma(Schweiz)AG(PERJETA)
  • 其他企業分析

第5章 中國的Pertuzumab醫藥品市場預測(2021-2025)

  • 中國的Pertuzumab市場開發的有影響力的要素
    • COVID-19對中國的Pertuzumab市場的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2106512

Pertuzumab is the first monoclonal antibody called "HER dimerization inhibitor". It mainly used to treat HER2-positive breast cancer. It was developed by Genentech, a subsidiary of Roche Pharma (Schweiz) AG, and was first approved in 2012. Pertuzumab entered the Chinese market in 2019. As of the first half of 2021, Roche Pharma (Schweiz) AG is the only manufacturer in the Chinese Pertuzumab market.

According to CRI's market research, since Pertuzumab entered the Chinese market, the sales grew rapidly, from CNY21.15 million in 2019 to CNY501.69 million in 2020. The annual growth rate of Pertuzumab's sales is 2272.15%.

CRI expects that based on the price reduction of Pertuzumab, its sales volume will continue to grow from 2021 to 2025. Pertuzumab was included in the medical insurance reimbursement catalog at the beginning of 2020, and the price of each 0.42g dose reduced from CNY18,800 to CNY4955. This price is valid until the end of 2021. The price of Pertuzumab is expected to be lowered again in the future. The price reduction will reduce the burden on patients, thereby increasing the usage rate of Pertuzumab and its sales. At the same time, the huge patient population will also enable the Pertuzumab market to continue to expand. Breast cancer is one of the top ten new cancer cases in China in 2020, reaching 420,000. Among them, HER2-positive patients accounted for 20%-30%. A large number of patients has also increased the demand for Pertuzumab. In addition, the effectiveness of the combination therapy of Pertuzumab and Trastuzumab has also laid down its potential in the market.

Topics Covered:

  • The impact of COVID-19 on China's Pertuzumab market
  • Sales value of China's Pertuzumab 2016-2020
  • Competitive landscape of China's Pertuzumab market
  • Prices of Pertuzumab in China
  • Prices of Pertuzumab in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Pertuzumab market
  • Prospect of China's Pertuzumab market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Pertuzumab

  • 1.1 Indications for Pertuzumab
  • 1.2 Development of Pertuzumab in China
  • 1.3 Governmental Approval of Pertuzumab in China
  • 1.4 The Impact of COVID-19 on Pertuzumab sales in China

2 Sales of Pertuzumab in China, 2019-2020

  • 2.1 Sales Value of Pertuzumab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Pertuzumab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Pertuzumab by Dosage Form in China, 2019-2020
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Pertuzumab Manufacturers in China, 2019-2020

  • 3.1 Analysis of Market Share of Major Pertuzumab Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Roche Pharma (Schweiz) AG
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of PERJETA (Roche Pharma (Schweiz) AG's Pertuzumab) in China

4 Prices of Pertuzumab for Different Manufacturers in China, 2020-2021

  • 4.1 Roche Pharma (Schweiz) AG (PERJETA)
  • 4.2 Analysis of Other Enterprises

5 Prospect of Chinese Pertuzumab drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Pertuzumab Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Pertuzumab Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Pertuzumab Injection Registration in China
  • Chart Sales Value of Pertuzumab Injection over the World
  • Chart Sales Value of Pertuzumab Injection in China, 2019-2020
  • Chart Sales Value of Pertuzumab Injection in China by Region, 2019-2020
  • Chart Sales Volume of Pertuzumab Injection in China, 2019-2020
  • Chart Sales Volume of Pertuzumab Injection in China by Region, 2019-2020
  • Chart Market Share by Sales Value of Top Pertuzumab Manufacturers in China, 2019-2020
  • Chart Sales Value and Volume of PERJETA in China, 2019-2020
  • Chart Referential Prices of PERJETA in China, 2020-2021
  • Chart Forecast on Sales Value of Pertuzumab in China, 2021-2025
  • Chart Forecast on Sales Volume of Pertuzumab in China, 2021-2025